首页> 外文OA文献 >Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema

【2h】

Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema

机译：基线视力和视网膜厚度的关联，具有1年的Aflibercept，Bevacizumab和Ranibizumab用于糖尿病黄斑水肿的疗效

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
John A. Wells; Adam R. Glassman; Lee M. Jampol; Lloyd Paul Aiello; Andrew N. Antoszyk; Carl W. Baker; Neil M. Bressler; David J. Browning; Crystal G. Connor; Michael J. Elman; Frederick L. Ferris; Scott M. Friedman; Michele Melia; Dante J. Pieramici; Jennifer K. Sun; Roy W. Beck;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema [J] . Wells John A., Glassman Adam R., Jampol Lee M., JAMA ophthalmology . 2016,第2期

机译：基线视力和视网膜厚度与阿柏西普，贝伐单抗和雷珠单抗治疗糖尿病性黄斑水肿1年疗效的关系
2. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema (vol 134, pg 127, 2016) [J] . Wells J. A., Glassman A. R., Jampol L. M. JAMA ophthalmology . 2016,第4期

机译：基线视力和视网膜厚度与阿柏西普，贝伐单抗和雷珠单抗治疗糖尿病性黄斑水肿的1年疗效的关系（第134卷，第127页，2016年）
3. Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial [J] . Bressler Neil M., Odia Isoken, Maguire Maureen, JAMA ophthalmology . 2019,第9期

机译：随机患者治疗糖尿病患者的糖尿病性黄斑水肿过程中的视力变化与中央子场厚度之间的关系，北伐自由素或雷尼贝里姆（Ranibizumab）：A术后临床试验的后HOC分析
4. Morphology of vascular network in eyes with diabetic macular edema varies based on tolerance of aflibercept treatment interval length: preliminary findings [C] . Prateek Prasanna, Justis Ehlers, Nathaniel Braman, Biomedical Applications in Molecular, Structural, and Functional Imaging . 2019

机译：患有糖尿病黄斑水肿的眼睛中血管网络的形态基于AfliBercept治疗间隔长度的耐受性因耐受性而变化：初步调查结果
5. Prediction of visual acuity loss and indications for laser treatment in patients with diabetic macular edema using the Heidelberg Retina Tomograph. [D] . O'Neal, Dennis A. 2007

机译：使用海德堡视网膜断层扫描仪预测糖尿病性黄斑水肿患者的视力下降和激光治疗的适应症。
6. Association of Baseline Visual Acuity and Retinal Thickness With 1-year Efficacy of Aflibercept Bevacizumab and Ranibizumab for Diabetic Macular Edema [O] . John A. Wells, Adam R. Glassman, Lee M. Jampol, -1

机译：基线视力和视网膜厚度与阿柏西普贝伐单抗和雷珠单抗治疗糖尿病性黄斑水肿的1年疗效的关系
7. Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab [O] . Neil M. Bressler, Isoken Odia, Maureen Maguire, 2019

机译：在Aflibercept，Bevacibizumab或Ranibizumab中的参与者治疗参与者中患有糖尿病黄斑水肿的视力变化与中央子场厚度之间的关系

Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema

著录项

相似文献

相关主题

期刊订阅